Raab and his team saw that 100% of minimal residual disease (MRD)–eligible patients achieved MRD-negative status at 10–5 and 10–6 thresholds at completion of induction. TranscriptCan you provide an overview of the MajesTEC-5 trial, including the patient population and results you would like to highlight? We mainly found, we're looking, of course, mainly for safety—that was the purpose of the trial—in different setups, combinations. Of course, the most important part is the efficacy, and we see tremendous efficacy with all patients tested, and that was 48 out of 49 patients. Only 1 patient could not be tested, but all patients tested reached MRD [minimal residual disease] negativity down to the 10–6 in all patients, so I think that speaks for itself.